--(BUSINESS WIRE)--Techulon is a life sciences company with a core capability in the development, characterization and synthesis of novel gene delivery techniques for cell-based therapeutics. Our proprietary nanoparticle delivery platform, Glycofect, is a polymer-based reagent that delivers DNA and RNA into cells with lower cell toxicity and high protein expression. The company is focused on delivery for therapeutically relevant cells such as primary cells. Applications for this new technology range from research on cellular metabolism to advanced forms of cancer treatment. First indications include neurodegenerative diseases and glioma.
